Cough, Refractory Chronic Cough
Conditions
Keywords
Respiration Disorders, Respiratory Tract Diseases, Signs and Symptoms, Respiratory, Cough, Chronic Cough
Brief summary
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Detailed description
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.
Interventions
DRUGBLU-5937
Oral administration of BLU-5937 Tablets
DRUGPlacebo
Oral administration of matching placebo for BLU-5937 Tablets
Sponsors
Bellus Health Inc. - a GSK company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Capable of giving signed informed consent * Refractory chronic cough (including unexplained chronic cough) for at least one year * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose
Exclusion criteria
* Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history * Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment * Respiratory tract infection within 4 weeks before screening * Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening * History of malignancy in the last 5 years * History of alcohol or drug abuse within the last 3 years * Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus. * Previous participation in a BLU-5937 trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 24 | Baseline, Week 24 | — |
| 24-Hour Cough Frequency | Week 24 | Assessed using an ambulatory cough monitor |
| Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 24 | Up to Week 24 | An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator. |
| Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 24 | Up to Week 24 | An AEMI is an event of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring is appropriate. The following are AEMIs for this study: taste disturbance, oral hypoesthesia, oral paresthesia, and new or worsening findings of the cornea. |
| Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 24 | Up to Week 24 | An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator. |
| Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 24 | Up to Week 24 | An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator. |
| Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 24 | Baseline, Week 24 | — |
| Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 24 | Baseline, Week 24 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Greater than or Equal to (>=) 30 mm Reduction From Baseline in Cough Severity Visual Analog Scale at Week 24 | Baseline, Week 24 | Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity. |
| Awake Cough Frequency at Week 24 | Week 24 | Assessed using an ambulatory cough monitor |
| Percentage of Participants With >= 30 percent (%) Reduction From Baseline in 24-Hour Cough Frequency at Week 24 | Baseline, Week 24 | Assessed using an ambulatory cough monitor |
| Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 24 | Baseline, Week 24 | The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life. |
| Percentage of Participants With a >= 1.3-point Increase From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 24 | Baseline, Week 24 | The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life. |
| Change from Baseline in the Chronic Cough Diary (CCD) Score at Week 24 | Baseline, Week 24 | The CCD is a participant-completed daily diary used to assess chronic cough. The CCD score ranges from 0 to 16, with a higher score indicating worse symptoms. |
| Percentage of Participants with CCD Response at Week 24 | Week 24 | Percentage of participants with CCD response will be summarized. |
| Change from Baseline in Cough Severity Visual Analogue Scale at Week 24 | Baseline, Week 24 | Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity. |
Countries
Australia, Canada, China, Czechia, Germany, India, Japan, New Zealand, Slovakia, South Korea, Taiwan, United Kingdom, United States
Contacts
Primary ContactUS GSK Clinical Trials Call Center
Backup ContactEU GSK Clinical Trials Call Center
Outcome results
None listed